BERKELEY, Calif. and VANCOUVER, British Columbia, February 7, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it will be attending BIO CEO & Investor Conference 2018. The conference will be held February 12-13, 2018 at New York Marriott Marquis Hotel …
BERKELEY, Calif. and VANCOUVER, British Columbia, February 6, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is pleased to announce the opening of a new clinical site, Jefferson Breast Care Center in Philadelphia, PA, and the appointment of Dr. Saveri Bhattacharya, a …
– Further Investigation on Mechanism of Action of its Lead Drug Candidate, Bria-IMT™, at AACR event – BERKELEY, Calif. and VANCOUVER, British Columbia, February 5, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, will present a poster on the mechanism of action …
BERKELEY, Calif. and VANCOUVER, British Columbia, January 31, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, provides an update on its operations. Recent Corporate Milestones Recent Clinical Update: BriaCell is pleased to provide a further update on its ongoing clinical trial of …
BERKELEY, Calif. and VANCOUVER, British Columbia, January 3, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, is providing a clinical update regarding its ongoing clinical trials of Bria-IMT™ (formerly referred to as SV-BR-1-GM). BriaCell currently is enrolling patients in two separate but …
BERKELEY, Calif. and VANCOUVER, British Columbia, January 2, 2018 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced that it will be attending Biotech Showcase™ 2018. The conference will be held January 8-10, 2018 at Hilton San Francisco Union Square (333 O’Farrell St, …
Berkeley, CA and Vancouver, BC – December 21, 2017 – BriaCell Therapeutics Corp. (“BriaCell” or the “Company“) (TSXV: BCT) (OTCQB: BCTXF) is pleased to announce it has closed the warrant incentive program (the “Warrant Incentive Program“) announced on October 13, 2017, intended to encourage the exercise of outstanding common share purchase warrants of the Company. …
BERKELEY, Calif. and VANCOUVER, British Columbia, Dec. 05, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V:BCT) (OTCQB:BCTXF), an immuno-oncology focused biotechnology company with a proprietary targeted immunotherapy technology, announced today that Dr. Bill Williams, BriaCell’s President & CEO, will appear as a guest on the radio show “CEO MONEY.” CEO MONEY, …
Click here to read more
BERKELEY, Calif. and VANCOUVER, British Columbia, November 13, 2017 (GLOBE NEWSWIRE) — BriaCell Therapeutics Corp. (“BriaCell” or the “Company”) (TSX-V: BCT) (OTCQB: BCTXF), an immuno-oncology focused biotechnology company with a proprietary vaccine technology, today disclosed the allowance by the US Patent and Trademark Office (USPTO) and also the European Patent Office (EPO) of two patent …